Table 3.
Stratified risk estimates of metabolic syndrome for the survival of digestive tract cancer.
| Metabolic syndrome | Studies | ES | 95% CI | P | I2 | P |
|---|---|---|---|---|---|---|
| Cancer type | ||||||
| CRC | 9 | 1.22 | 0.96 to 1.55 | 0.112 | 93.1% | < 0.001 |
| ESCC | 4 | 0.97 | 0.60 to 1.57 | 0.897 | 86.1% | < 0.001 |
| GC | 3 | 1.53 | 0.95 to 1.49 | 0.411 | 94.8% | < 0.001 |
| Complete surgery | ||||||
| No | 5 | 0.91 | 0.81 to 1.02 | 0.097 | 53.0% | 0.074 |
| Yes | 11 | 1.42 | 1.06 to 1.92 | 0.020 | 91.0% | < 0.001 |
| Total sample size | ||||||
| < 1000 | 7 | 1.00 | 0.66 to 1.51 | 0.998 | 82.9% | < 0.001 |
| ≥1000 | 9 | 1.33 | 0.99 to 1.78 | 0.056 | 96.8% | < 0.001 |
| Ethnicity | ||||||
| Chinese | 12 | 1.16 | 0.89 to 1.50 | 0.282 | 96.1% | < 0.001 |
| Non-chinese | 4 | 1.29 | 0.89 to 1.87 | 0.174 | 51.3% | < 0.001 |
| Study design | ||||||
| Prospective | 6 | 1.64 | 1.18 to 2.28 | 0.003 | 91.4% | < 0.001 |
| Retrospective | 10 | 0.94 | 0.84 to 1.11 | 0.469 | 76.2% | < 0.001 |
| Tnm stage | ||||||
| I-III | 9 | 1.07 | 0.85 to 1.36 | 0.550 | 76.1% | < 0.001 |
| I-IV | 7 | 1.36 | 0.93 to 1.99 | 0.116 | 97.6% | < 0.001 |
| Follow-up period | ||||||
| < 43 months | 8 | 1.19 | 0.84 to 1.69 | 0.326 | 91.3% | < 0.001 |
| ≥ 43 months | 8 | 1.18 | 0.86 to 1.56 | 0.262 | 94.2% | < 0.001 |
| Survival outcome | ||||||
| Cancer-specific survival | 5 | 1.91 | 1.45 to 2.52 | < 0.001 | 85.8% | < 0.001 |
| Overall survival | 11 | 0.93 | 0.81 to 1.06 | 0.270 | 68.4% | < 0.001 |
ES, effect size; 95% CI, 95% confidence interval; I2, inconsistency index; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; TNM, tumor node metastasis.